Linc
Linc AB is a Stockholm-based, Nasdaq Stockholm-listed Swedish investment company that invests SEK 25–250 million in product-oriented Nordic life science companies, primarily pharmaceuticals and medical technology, as an active permanent-capital owner.
- Company typePublic
- Founded2021
- HeadquartersStockholm, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Linc does
Linc AB is a Swedish publicly listed investment company (publ) on Nasdaq Stockholm (STO:LINC), headquartered in Stockholm, Sweden. The firm invests in product-oriented companies across the Nordic life science industry — primarily in pharmaceuticals and medical technology — providing capital and active ownership support to both early-stage drug development companies and more mature medtech businesses. Linc positions itself not as a traditional venture fund but as a permanent-capital vehicle with an unlimited ownership horizon, targeting individual investments of SEK 25–250 million.
Linc's business model centers on equity investment and active ownership rather than product sales or subscription pricing. The company generates economic returns through portfolio company exits, dividends, capital appreciation, and refinancing, while its listed status provides a continuous capital pool. Per the end-2021 disclosure, Linc's net asset value stood at approximately SEK 3.6 billion (SEK 3.6 MDSEK). Revenue mechanics typical of an operating company (product pricing, ARR, GMV) do not apply; financial outcomes flow through NAV movements and exit-driven realizations.
Linc's value proposition combines capital with active ownership support: access to Nordic and international research and government networks, board representation, credibility with banks and partners, management recruitment, and a pragmatic, business-oriented partnership model. The firm's geographic mandate spans Sweden, Denmark, Norway, and Finland. It has a small operating team (1–10 employees) led by CEO Karl Tobieson, CFO Thomas Bergh, and Chairman Bengt Julander, and disclosed notable portfolio activity including the 2014 acquisition of Stille and financial backing of Medivir AB's approximately SEK 140 million directed share issue.
Linc firmographics
Firmographics- Name
- Linc
- Legal name
- Linc AB
- Website
- https://linc.se
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Linc AB is a Stockholm-based, Nasdaq Stockholm-listed Swedish investment company that invests SEK 25–250 million in product-oriented Nordic life science companies, primarily pharmaceuticals and medical technology, as an active permanent-capital owner.
- Ownership category
- akta.pro rank
Linc industry classification
Industry- Product category
- Life Science Investment
- NAICS
- All Other Financial Investment Activities (52399), Miscellaneous Financial Investment Activities (523999), Management of Companies and Enterprises (551)
- SIC
- Investors, Nec (6799), Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
Keywords
Where Linc is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Linc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Distribution channels1 record
Marketing channels4 records
Linc product offering
Product offeringCore offering
Linc AB is a publicly listed investment company that provides equity capital and active ownership to product-oriented companies in the Nordic Life Science industry — primarily pharmaceutical and medical technology companies. Typical investment sizes range from SEK 25 million to SEK 250 million, with pharmaceutical investments typically occurring at an early stage and medical technology investments in more mature companies. In addition to capital, Linc provides active ownership services to its portfolio companies, including board appointments, strategic guidance, access to national and international networks across research institutions, government agencies, and academia, and support in recruitment of new management. The firm operates with an unlimited ownership horizon and positions itself as a pragmatic, business-oriented partner to entrepreneurs, management, and co-investors.
Product overview
Linc is an investment company that invests in product-oriented Nordic Life Science companies, primarily in pharmaceuticals and medical technology. It is not a product/software company — it operates as an active owner providing capital, expertise, networks, and industrial competence to portfolio companies. Investments typically range from SEK 25-250 million, targeting early-stage pharmaceutical companies and more mature medtech companies. The company had a NAV of approximately SEK 3.6 billion at the end of 2021 and completed its IPO on Nasdaq Stockholm in May 2021.
Differentiator
Problem solved
Functional benefit
Products and services
- Equity investment in Nordic pharmaceutical companies Equity capital investment of typically SEK 25 to 250 million per company, targeting product-oriented Nordic pharmaceutical companies at an early stage of drug development, combined with active ownership support. Intended for founders, management teams, and boards of Nordic pharma companies.
- Equity investment in Nordic medical technology companies Equity capital investment of typically SEK 25 to 250 million per company, targeting product-oriented Nordic medical technology companies at a more mature stage than typical pharma investments, combined with active ownership support. Intended for founders, management teams, and boards of Nordic medtech companies seeking scale-up capital.
- Active ownership and board support for portfolio companies Active ownership services provided to portfolio companies following investment, including board appointments and participation, ongoing monitoring against an agreed company plan in close collaboration with portfolio management, recruitment support for new management when required, and access to Linc's national and international network across research, government agencies, universities, and industry partners. Delivered under an unlimited ownership horizon.
Companies that use Linc
Customer profileSegments3 records
Ideal customer profiles2 records
Linc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Linc partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Linc competitors and assessment
Company assessmentDirect peers
- HealthCap: HealthCap is a Nordic/European venture capital firm investing in life science companies across pharma, medtech, and diagnostics. Most direct peer to Linc given overlapping Nordic life science mandate and similar active-ownership approach.
- Sunstone Capital: Sunstone Capital is a Danish/Nordic life science venture capital firm investing in early-stage therapeutic and medical device companies. Comparable to Linc's Nordic life science specialization and stage focus.
- Novo Holdings (Novo Seeds): Novo Holdings is the holding company of the Novo Nordisk Foundation and runs Novo Seeds, investing in early-stage life science companies. Highly comparable given Nordic focus, pharma/medtech scope, and active-ownership style.
- Industrifonden: Industrifonden is a Swedish venture capital investor with significant Nordic life science exposure across pharma and medtech. Direct peer operating in the same Nordic life science investment universe.
- Karolinska Development: Karolinska Development is a Swedish listed investment company focused on Nordic life science, particularly early-stage pharma and medtech companies from Karolinska Institute research. Most direct peer given listed structure and Nordic life science focus.
Broad incumbents
- EQT Life Sciences: EQT Life Sciences (formerly LSP) is a leading European life sciences investor with global reach. Broader scope and larger fund sizes than Linc, but operates in the same pharma/medtech investment thesis.
- Swedish Investment Company peers - Lundbergs: Lundbergs is a Swedish family-controlled listed investment company. While not life science focused, it serves as a structural peer for the Swedish listed-investment-company governance and capital-allocation model Linc employs.
- Investor AB (Wallenberg): Investor AB is a Swedish listed investment company with significant healthcare and life science exposure across its portfolio. A broader incumbent operating the same Swedish listed-investment-company structure with active ownership.
Emerging players
- BioInvent International: BioInvent is a Swedish biotech company developing immuno-modulatory antibodies for cancer. While an operating company rather than investor, it represents the type of Nordic clinical-stage life science asset that Linc targets and partners with.
- Aller Media / Bactiguard investment peers - Bactiguard Holding: Bactiguard is a Swedish medtech company specializing in infection prevention. It represents the type of mature Nordic medtech asset that Linc's medical technology investment vertical targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Linc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Linc leadership team
Management profileNumber of profiles
Profiles3 records
Linc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Linc M&A and investment
M&A and investmentM&A1 record
Investments12 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Linc
What does Linc do?
Linc AB is a publicly listed investment company that provides equity capital and active ownership to product-oriented companies in the Nordic Life Science industry — primarily pharmaceutical and medical technology companies. Typical investment sizes range from SEK 25 million to SEK 250 million, with pharmaceutical investments typically occurring at an early stage and medical technology investments in more mature companies. In addition to capital, Linc provides active ownership services to its portfolio companies, including board appointments, strategic guidance, access to national and international networks across research institutions, government agencies, and academia, and support in recruitment of new management. The firm operates with an unlimited ownership horizon and positions itself as a pragmatic, business-oriented partner to entrepreneurs, management, and co-investors.
Is Linc a public or private company?
Linc is a public company. It is classified as public and is currently operating.
When was Linc founded?
Linc was founded in 2021. It employs 1 to 10 people.
Where is Linc based?
Linc is headquartered in Stockholm, Sweden, in the Europe region.
Who are Linc's main competitors?
Direct peers on record are HealthCap, Sunstone Capital, Novo Holdings (Novo Seeds), Industrifonden and Karolinska Development. Broad incumbents are EQT Life Sciences, Swedish Investment Company peers - Lundbergs and Investor AB (Wallenberg). Emerging players are BioInvent International and Aller Media / Bactiguard investment peers - Bactiguard Holding.
Does Linc have an API?
No public API is recorded for Linc.
What industry is Linc in?
Linc's product category is Life Science Investment. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 52399 and its SIC code is 6799.